Form 483

Bora Pharmaceuticals Injectables Inc Form 483, 2011-07-22

FDA issued a Form 483 to Bora Pharmaceuticals Injectables Inc on 2011-07-22 with 4 public-safe observations.

483· Form 483 issued4 observations

Bora Pharmaceuticals Injectables Inc · Baltimore, United States · Issued July 22, 2011

Overview

  • 4 public-safe observations are available for this inspection.
  • 4 structured CFR citations are represented.
  • 4 investigators are tied to this Form 483.

Inspectional observations

Each observation cites the regulation FDA found the firm out of compliance with.

22 Jul 2011
21 CFR 211.25(a)

Training , Education , Experience overall

Cited by William A Warnick, Rachel C Harrington, Brooke K Higgins, Ernest Bizjak

22 Jul 2011
21 CFR 211.63

Equipment Design, Size and Location

Cited by William A Warnick, Rachel C Harrington, Brooke K Higgins, Ernest Bizjak

22 Jul 2011
21 CFR 211.67(b)

Written procedures not established/followed

Cited by William A Warnick, Rachel C Harrington, Brooke K Higgins, Ernest Bizjak

22 Jul 2011
21 CFR 211.113(b)

Procedures for sterile drug products

Cited by William A Warnick, Rachel C Harrington, Brooke K Higgins, Ernest Bizjak

Inspected site

BPBora Pharmaceuticals Injectables IncBaltimore, United States

Inspection team

Cited regulations

CFR citations associated with this Form 483.

CitationWhat it coversCited
21 CFR 211.113(b)Cited across public-safe Form 483 observations1x
21 CFR 211.25(a)Cited across public-safe Form 483 observations1x
21 CFR 211.63Cited across public-safe Form 483 observations1x
21 CFR 211.67(b)Cited across public-safe Form 483 observations1x

Source document

PDF
PDF available

Form 483 source document

The source document is available to authorized Atlas users.

Full 483 report

Get the verbatim text of all 4 observations

The source PDF and every observation in full, so your team sees exactly what was cited and how it was answered.

  • The site's full inspection history around this Form 483
  • Whether these citations escalated to a warning letter
  • The investigators involved and the citations they repeat elsewhere